Skip to main content
IncytePartnership

Wilmington’s Incyte Partners With Natera on Phase 2 Colorectal Cancer Trial Guided by MRD Testing

Source: Autobound Signal API · 75 signals tracked for Incyte · updated

Get Incyte's live signals in Claude or ChatGPT, or by API

AskWhat changed at Incyte this week? Use Autobound signals for incyte.com.

What happened

Incyte entered into a clinical collaboration agreement with Natera to use its Signatera blood test to identify patients for a Phase 2 colorectal cancer trial evaluating investigational immunotherapy INCA33890.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Incyte, the Wilmington, Delaware-based biopharmaceutical company, will use Natera 's Signatera™ blood test to identify patients for a new Phase 2 colorectal cancer (CRC) trial of its investigational immunotherapy, Natera announced on November 10, 2026. Under a clinical collaboration agreement, the trial will evaluate Incyte's INCA33890, an investigational bispecific immunotherapy, in patients whose cancer shows signs of returning before it appears on scans. "Patients with colorectal cancer who remain MRD-positive after surgery and chemotherapy represent a population with substantial unmet need and a significantly elevated risk of recurrence," said Lois Erskine, Vice President and INCA 33890 Global Program Head at Incyte. The study will enroll patients with stage 2 or stage 3 CRC who have completed surgery and adjuvant chemotherapy (ACT), the chemotherapy given after surgery. After ACT, patients will be monitored with Signatera for up to 12 months. Signatera detects molecular residual disease (MRD), small traces of cancer that remain after treatment. Patients who test MRD-positive but show no evidence of cancer on imaging may be eligible to enroll and receive INCA33890. Signatera will also serve as both a primary and secondary endpoint in the trial. Natera's clinical and real-world evidence and its experience designing MRD-guided trials helped inform the study. Natera will...

Keep reading with a free account

The rest of this article, and every signal for Incyte, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

Takes effect
Nov 10, 2026
Location
Wilmington, Delaware, United States

Companies

  • NateraPartnernatera.com

More partnership signals at other companies

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Nov 12, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for Incyte and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/083c9cb9-3a1b-b0ff-6432-8bd2913850ba returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.

{
  "signal_id": "083c9cb9-3a1b-b0ff-6432-8bd2913850ba",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-11-12T05:08:01+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "url": "https://biobuzz.io/news/natera-announces-clinical-collaboration-with-incyte-on-interventional-phase-ii-study-in/",
    "title": "Wilmington’s Incyte Partners With Natera on Phase 2 Colorectal Cancer Trial Guided by MRD Testing - BioBuzz",
    "excerpt": "Incyte , the Wilmington, Delaware-based biopharmaceutical company, will use Natera ’s Signatera™ blood test to identify patients for a new Phase 2 colorectal cancer (CRC) trial of its investigational immunotherapy, Natera announced on November 10, 2026 . Under a clinical collaboration agreement, the trial will evaluate Incyte’s INCA33890, an investigational bispecific immunotherapy, in patients whose cancer shows signs of returning before it appears on scans. “Patients with colorectal cancer who remain MRD-positive after surgery and chemotherapy represent a population with substantial unmet need and a significantly elevated risk of recurrence,” said Lois Erskine , Vice President and INCA 33890 Global Program Head at Incyte. The study will enroll patients with stage 2 or stage 3 CRC who have completed surgery and adjuvant chemotherapy (ACT), the chemotherapy given after surgery. After ACT, patients will be monitored with Signatera for up to 12 months. Signatera detects molecular residual disease (MRD), small traces of cancer that remain after treatment. Patients who test MRD-positive but show no evidence of cancer on imaging may be eligible to enroll and receive INCA33890. Signatera will also serve as both a primary and secondary endpoint in the trial. Natera’s clinical and real-world evidence and its experience designing MRD-guided trials helped inform the study. Natera will...",
    "summary": "Incyte entered into a clinical collaboration agreement with Natera to use its Signatera blood test to identify patients for a Phase 2 colorectal cancer trial evaluating investigational immunotherapy INCA33890.",
    "location": "Wilmington, Delaware, United States",
    "planning": false,
    "image_url": "https://biobuzz.io/wp-content/uploads/2026/11/Article-Graphics-53.png",
    "confidence": 0.95,
    "published_at": "2026-11-12T05:08:01Z",
    "location_data": [
      {
        "city": "Wilmington",
        "state": "Delaware",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-10",
    "article_sentence": "Under a clinical collaboration agreement, the trial will evaluate Incyte’s INCA33890, an investigational bispecific immunotherapy, in patients whose cancer shows signs of returning before it appears on scans.",
    "related_company_name": "Natera",
    "related_company_domain": "natera.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.